MUROMONAB-CD3

Summary

Muromonab-Cd3 (CHEMBL1201608) is an approved unknown (ATC L04AG01) targeting CD3E; indicated across 9 conditions including cutaneous melanoma and melanoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• ATC class: L04AG01
• Targets: 1 (CD3E)
• Indications: 9 conditions
• Clinical trials: 19

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201608
Name	MUROMONAB-CD3
Type	Unknown
Max phase	4
ATC	L04AG01

Also known as: Anticd3, L04AA02, Macs gmp cd3 pure, Muromomab, Muromonab, Muromonab cd3, Muromonab-cd3, OKT-3, OKT3, Orthoclone okt3, MUROMONAB-CD3, MURUMONAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CD3E	CD3e	Binding		0%	P07766

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): CD3E.

Top Reactome pathways

10 total, by targets touching each:

Pathway	Targets	Genes
Adaptive Immune System	1	CD3E
Immune System	1	CD3E
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	1	CD3E
TCR signaling	1	CD3E
Downstream TCR signaling	1	CD3E
Phosphorylation of CD3 and TCR zeta chains	1	CD3E
Translocation of ZAP-70 to Immunological synapse	1	CD3E
Generation of second messenger molecules	1	CD3E
Regulation of T cell activation by CD28 family	1	CD3E
Co-inhibition by PD-1	1	CD3E

Dominant GO biological processes

GO term	Targets
positive regulation of cell-matrix adhesion	1
adaptive immune response	1
positive regulation of T cell anergy	1
T cell anergy	1
cell surface receptor signaling pathway	1
cell surface receptor protein tyrosine kinase signaling pathway	1
signal complex assembly	1
G protein-coupled receptor signaling pathway	1
smoothened signaling pathway	1
positive regulation of gene expression	1
negative regulation of gene expression	1
dendrite development	1
calcium-mediated signaling	1
cerebellum development	1
T cell costimulation	1

Indications & clinical

Indications

9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cutaneous melanoma	2	MONDO:0005012	EFO:0000389
melanoma	2	MONDO:0005105	EFO:0000756
kidney neoplasm	2	MONDO:0021163	EFO:0003865
metabolic dysfunction-associated steatohepatitis	2	MONDO:0007027	EFO:1001249
central nervous system neoplasm	2	MONDO:0006130	EFO:1000158
kidney cancer	2	MONDO:0002367	MONDO:0002367
neoplasm	1	MONDO:0005070	EFO:0000616
ulcerative colitis	1	MONDO:0005101	EFO:0000729

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 19.

Phase distribution

Phase	Trials
PHASE2	9
PHASE1	4
PHASE1/PHASE2	3
PHASE3	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01423500	PHASE3	UNKNOWN	ALL-SCT BFM International- HSCT in Children and Adolescents With ALL
NCT01423747	PHASE3	UNKNOWN	Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia
NCT00002482	PHASE1/PHASE2	UNKNOWN	Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer
NCT00002589	PHASE2	UNKNOWN	Lymphocyte Therapy in Treating Patients With Kidney Cancer
NCT00004022	PHASE2	COMPLETED	Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma
NCT00004024	PHASE2	COMPLETED	Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma
NCT00004482	PHASE2	COMPLETED	Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis
NCT00005852	PHASE2	TERMINATED	Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant
NCT00080353	PHASE2	COMPLETED	Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma
NCT00202917	PHASE1/PHASE2	COMPLETED	Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies
NCT00450983	PHASE2	TERMINATED	Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
NCT00566696	PHASE2	COMPLETED	Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
NCT01205087	PHASE2	COMPLETED	Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome
NCT01287195	PHASE1/PHASE2	COMPLETED	Oral OKT3 for the Treatment of Active Ulcerative Colitis
NCT00002572	PHASE1	COMPLETED	Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors
NCT00091611	PHASE1	TERMINATED	Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
NCT00619372	PHASE1	UNKNOWN	Oral OKT3 in Combination With Beta-D-Glucosylceramide
NCT00824135	PHASE1	COMPLETED	Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies
NCT00027443	Not specified	COMPLETED	Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).